Shanghai Bio-heart Biological Technology (2185) Stock Overview
Shanghai Bio-heart Biological Technology Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
2185 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Shanghai Bio-heart Biological Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.83 |
| 52 Week High | HK$10.77 |
| 52 Week Low | HK$1.43 |
| Beta | -0.085 |
| 1 Month Change | -21.53% |
| 3 Month Change | -23.29% |
| 1 Year Change | 264.38% |
| 3 Year Change | -12.20% |
| 5 Year Change | n/a |
| Change since IPO | -70.99% |
Recent News & Updates
Recent updates
We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth
Nov 15
Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans
Jul 24Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth
Feb 22Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth
Nov 03We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth
May 12We're Not Worried About Shanghai Bio-heart Biological Technology's (HKG:2185) Cash Burn
Sep 19Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans
Jun 03Shareholder Returns
| 2185 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | -10.6% | -3.1% | -1.7% |
| 1Y | 264.4% | 50.1% | 29.4% |
Return vs Industry: 2185 exceeded the Hong Kong Medical Equipment industry which returned 50.1% over the past year.
Return vs Market: 2185 exceeded the Hong Kong Market which returned 29.4% over the past year.
Price Volatility
| 2185 volatility | |
|---|---|
| 2185 Average Weekly Movement | 13.1% |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in HK Market | 14.3% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 2185's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2185's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 70 | Philip Wang | www.bio-heart.com |
Shanghai Bio-heart Biological Technology Co., Ltd. an interventional cardiovascular device company, engages in the research and development of therapies for unmet medical needs of patients in the People’s Republic of China. The company develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis.
Shanghai Bio-heart Biological Technology Co., Ltd. Fundamentals Summary
| 2185 fundamental statistics | |
|---|---|
| Market cap | HK$1.42b |
| Earnings (TTM) | -HK$98.65m |
| Revenue (TTM) | HK$23.04m |
Is 2185 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2185 income statement (TTM) | |
|---|---|
| Revenue | CN¥20.86m |
| Cost of Revenue | CN¥11.17m |
| Gross Profit | CN¥9.70m |
| Other Expenses | CN¥99.02m |
| Earnings | -CN¥89.33m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 46.47% |
| Net Profit Margin | -428.18% |
| Debt/Equity Ratio | 0% |
How did 2185 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 01:40 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Bio-heart Biological Technology Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nico Chen | DBS Bank Ltd |
| Wen Dai | Huatai Research |
| Tielin Chen | Topsperity Securities |